论文部分内容阅读
过去20年,肺癌的诊断和治疗发生了巨大的变化。随着CT检查的普及,肺癌的早期诊断率越来越高,但仍然有近30.0%的非小细胞新发肺癌患者存在纵隔淋巴结转移(N2 disease),由于单独手术的预后不佳~([1]),诱导治疗+手术为主的多学科综合治疗是目前治疗N2期非小细胞肺癌的主流策略,但是在具体治疗方案上存在较多争议。一、N2的诊断:有创和无创非小细胞肺癌纵隔淋巴结(N2)转移是一类异质
Over the past 20 years, the diagnosis and treatment of lung cancer have undergone tremendous changes. With the popularization of CT examination, the early diagnosis rate of lung cancer is getting higher and higher, but there are still nearly 30% of patients with non-small cell lung cancer with mediastinal lymph node metastasis (N2 disease). Due to the poor prognosis of single surgery, 1]), induction therapy + surgery-based multidisciplinary comprehensive treatment is the current mainstream of treatment of N2 non-small cell lung cancer strategy, but there are more controversial in the specific treatment options. First, the diagnosis of N2: invasive and non-invasive non-small cell lung cancer mediastinal lymph node (N2) transfer is a heterogeneous